

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)



(10) International Publication Number
WO 2021/226249 A1

(51) International Patent Classification:

C07K 16/10 (2006.01) *A61P 31/12* (2006.01)
C07K 14/165 (2006.01)

(21) International Application Number:

PCT/US2021/030909

(22) International Filing Date:

05 May 2021 (05.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/020,952	06 May 2020 (06.05.2020)	US
63/027,812	20 May 2020 (20.05.2020)	US
63/063,017	07 August 2020 (07.08.2020)	US
63/084,550	28 September 2020 (28.09.2020)	US
63/085,037	29 September 2020 (29.09.2020)	US

(71) Applicant: **SORRENTO THERAPEUTICS, INC.**
[US/US]; 4955 Directors Place, San Diego, California
92121 (US).

(72) Inventors: **ZHOU, Heyue**; 4955 Directors Place, San
Diego, California 92121 (US). **CAO, Xia**; 4955 Direc-
tors Place, San Diego, California 92121 (US). **LU, Lucy**;
4955 Directors Place, San Diego, California 92121 (US).
YAN, Ying; 4955 Directors Place, San Diego, California
92121 (US). **ZHANG, Yanliang**; 4955 Directors Place,
San Diego, California 92121 (US). **Ji, Henry Hongjun**;
4955 Directors Place, San Diego, California 92121 (US).
ALLEN, Robert; 4955 Directors Place, San Diego, Cali-
fornia 92121 (US).

(74) Agent: **BREIER, Adam M.** et al.; McNeill Baur PLLC,
125 Cambridge Park Drive, Suite 301, Cambridge, Massa-
chusetts 02140 (US).

(54) Title: NEUTRALIZING ANTIBODIES THAT BIND THE SARS-COV-2 S PROTEIN




FIG. 1

(57) Abstract: The present disclosure provides antigen-binding proteins, such as fully human antibodies, that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus and uses thereof. In various embodiments, the anti-spike protein antibodies are neutralizing antibodies that prevent binding of the SARS-CoV-2 coronavirus to a target cell expressing the ACE2 protein. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Also provided herein are nucleic acids and recombinant expression vectors that encode the anti-spike protein antibodies and antibody fragments disclosed herein and transgenic cells transected with such nucleic acids and expression vectors. Further provided are methods for preparing and using such anti-spike protein antibodies. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by

[Continued on next page]

WO 2021/226249 A1

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))